New hope for Tough-to-Treat lung cancer? trial tests targeted drug combo
NCT ID NCT07463677
Summary
This study is testing a new combination of drugs (tunlametinib plus others) for people with advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation and has stopped responding to standard treatments. It aims to see if this combination can shrink tumors and control the cancer for longer, while monitoring side effects. The study will enroll about 55 adults whose cancer has spread and cannot be surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.